Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03814733 · ClinicalTrials.gov registry record · Phase 1
Assessment of Effect of Rapastinel on Driving Performance
A Phase 1 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT03814733: Completed Phase 1 study, sponsored by Naurex, Inc, an affiliate of Allergan.
NCT03814733 is a Phase 1 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 107 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03814733, a Phase 1 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy participants.
Interventions
- DRUG Ketamine
- DRUG Alprazolam
- DRUG Rapastinel
- DRUG Rapastinel Matched Placebo
- DRUG Alprazolam Matched Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2018-11-05 |
| Est. Completion | 2019-04-03 |
| Phase | Phase 1 |
What the finished NCT03814733 record still lists
NCT03814733 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 5 interventions - of which Ketamine is the first listed.
NCT03814733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03814733 about?
NCT03814733 is a clinical study titled "Assessment of Effect of Rapastinel on Driving Performance". Based on the pharmacological class of rapastinel, this study will be conducted to evaluate the participant's driving performance after single IV doses of rapastinel as compared with single oral doses of alprazolam, a benzodiazepine that demonstrates driving impairment, and placebo in healthy partici...
What is the current status of trial NCT03814733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2018-11-05. Estimated completion is 2019-04-03.
What interventions are being tested in trial NCT03814733?
The interventions under investigation include: Ketamine (DRUG), Alprazolam (DRUG), Rapastinel (DRUG), Rapastinel Matched Placebo (DRUG), Alprazolam Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT03814733?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03814733's enrollment target sits among peer trials
107 531st of 2000 higher than 1,470 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI